To assess whether LCL161 could provide costimulatory benefit when TAC T cells were co-cultured with myeloma cells, we stimulated T cells with BCMA+ MM.1S myeloma tumor cells in the presence or absence of 0.625 μM LCL161. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.